| Dokumendiregister | Ravimiamet |
| Viit | REP-1/2188-1 |
| Registreeritud | 29.04.2025 |
| Sünkroonitud | 30.04.2025 |
| Liik | Sissetulev kiri |
| Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
| Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
| Toimik | REP-1/2025 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | European Directorate for the Quality of Medicines & HealthCare |
| Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
| Vastutaja | Signe Leito (RA, Peadirektori asetäitja valdkond, Labor) |
| Originaal | Ava uues aknas |
1
Signe Leito
Saatja: [email protected] Saatmisaeg: esmaspäev, 28. aprill 2025 15:21 Adressaat: Signe Leito Teema: Survey: Addition to the work programme (P1 procedure): Citicoline sodium: EDQM-2025-01794-mail
Please make sure to include in any reply our mail reference: EDQM-2025-01794-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear Colleagues, Please find below the link to a survey being carried out concerning the proposed addition of Citicoline sodium to the work programme of Group 11.
In order to have access to the survey, please copy and paste the following link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=257437&lang=en Deadline for replies: 28 May 2025. Thank you. Best regards, On behalf of Aurelie BARTH Andreea Mocoi Administrative Support Assistant European Pharmacopoeia Department EDQM Council of Europe Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://www.edqm.eu/store
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
2
Stay connected with the EDQM **************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2025-01794-mail